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Abstract 
 
 
 
HIV-1 replication depends on the insertion of a cDNA copy of the viral genome into the host 
genome. This process is catalyzed by the viral integrase (IN), in a two-step process- 
 
3’processing and strand transfer reaction. Lens epithelium-derived growth factor 
(LEDGF)/p75 is an important cellular co-factor for human immunodeficiency virus-1 (HIV-
1) replication which plays a crucial role during HIV-1 cDNA integration. The C-terminal 
integrase binding domain (IBD) of LEDGF/p75 interacts with CCD of HIV-1 Integrase (IN). 
In this study, based on the co-crystal structure of IN-LEDGF/p75, Methionine residue at 
position 178 of HIV-1 IN has been mutated to isoleucine. The M178I mutant IN awas 
analyzed for interaction with IBD of LEDGF/p75 in the pull down assays. Compared to wild 
type IN, M178I mutant show a ~90% reduction in interaction with IBD. Pull down result 
shows that M178I is an important residue which participates in interaction with IBD of 
LEDGF/p75. 
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CTD C-terminal domain  
HT His tag  
PIC preintegration complex  
IBD Integrase binding domain  
LEDGF/p75 Lens epithelium derived growth factor  
HIV-1 Human Immunodeficiency Syndrome  
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SP1 spacer peptide 1, 
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PR protease 
 
RT reverse transcriptase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V 
Contents 
 
 
Declaration .................................................................................................................... i 
 
Approval Sheet .............................................................................................................. ii 
 
Acknowledgements ...................................................................................................... iii 
 
Abstract ....................................................................................................................... iv 
 
Abbreviation ................................................................................................................. v 
 
1 Introduction ................................................................................................................ 1 
 
1.1 Structure of HIV-1  virus ...................................................................................... 1 
 
1.2 HIV-1 integrase .................................................................................................... 1 
 
1.3  two–domain structure of HIV-1 integrase …………………………………….. …..4  
1.4 function of catalytic centre motif of integrase protein (DD35E) ............................... 5 
 
1.5 Mechanism of retroviral DNA integration .............................................................. 6 
 
1.6 Integrase mutants .................................................................................................. 8 
 
1.7 LEDGF/p75  ……………………………………………………………………  ….8  
 
1.8 Hypothesis……………………………………………………………….………… 11  
 
1.9 Objective……………………………………………….………………………………..12  
 
 
 
2  Materials and methods…………………………………………………………………....13 
 
2.1 Construction of site-directed IN1-288/M178I mutant ........................ …….  …  …13 
 
2.2 Digestion ...........................................................................................................13 
 
2.3 Ligation .............................................................................................................14 
 
2.4 Screening of plasmid. .........................................................................................14 
 
2.5 Mini prep by alkaline lysis method. .....................................................................14 
 
2.6 Screening of clone………………………………………………………………  …15  
 
2.7 Screening of of mutant………………………………………………………………..15  
 
2.8 Insert release……………………………………………………………………… ….15  
 
2.9 Expression of protein……………………………………………………………… …16  
 
2.10 Pull down……………………………………………………………………………16  
 
 
 
 
VI 
3 Result and discussion……………………………………………………………………17 
 
3.1 Site directed mutagenesis of HIV-1 at Met178 residue to Ile…………………….17  
 
3.2 Screening of clone and mutation…………………………………………………. 18  
 
3.3 Protein purification of IN1-288/M178I……………………………………………. 20  
 
3.4 Pull down……………………………………………………………………………..21  
 
3.5 Discussion…………………………………………………………………………… 21  
 
4 Conclusion…………………………………………………………………………………22 
 
References.................................................... ………………….…………………………. 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
Chapter 1 
 
 
 
INTRODUCTION 
 
HIV-1 is a Lentivirus, a member of Retrovirus family which causes the acquired 
immunodeficiency syndrdrome (AIDS)(Weiss  1993). HIV infects immune cells in the human 
immune system such as helper T cells (CD4+ T cells), macrophages, and dendritic cells. 
These cells act as reservoir of HIV virus and increase the latency period and lead to AIDS  
(Stevenson 2003). Infection of HIV-1 virus causes decrease in the CD4+ cells. When CD4
+
 T 
cell numbers decline below a critical level, cell mediated immunity is lost, and the body 
becomes progressively more susceptible to infections 
 
 
1.1 STRUCTURE OF HIV-1 VIRUS 
 
HIV-1 is roughly spherical. The outermost covering is a lipid bilayer called the envelope, 
which is derived from the plasma membrane of the human host cell where the virus was 
produced. The outer surface of the HIV-1 contains a type of surface proteins composed of the 
two peptides gp41 and gp120. Portion of gp120 interacts with the CD4 receptor on the human 
host cell and is the first step in the life cycle of HIV-1. Below the lipid envelope of HIV-1 
there are two different layers of protein. The outer protein layer is known as the matrix and is 
made up of the MA protein. The inner protein layer is called the capsid and is composed of 
the CA protein. The capsid surrounds the core, which, in turn, contains two copies of the viral 
RNA genome and associated viral proteins including reverse transcriptase and integrase. 
 
HIV-1 contains two copies of the viral RNA genome which encodes nine genes (gag, pol, tat, 
env, rev, nef, vif, vpr and vpu). These nine genes encode 15 proteins. Gag encodes Gag 
polyprotein. The polyprotein is subsequently proteolysed by viral protease into MA (matrix 
protein, p17), CA (capsid protein, p24), NC (nucleocapsid protein, p7) and p6. Pol encodes 
three proteins PR (protease), IN (integrase) and RT (reverse transcriptase). Gene env encodes 
two proteins, SU and TM, these two proteins are structural component and form outer 
membrane envelope. Virus encodes additional proteins called accessory proteins: vif, vpr, 
vpu and Nef present in viral particle. Tat and Rev work as regulatory proteins  (Frankel and  
Young 1998). 
 
 
1.2 HIV-1 INTEGRASE 
 
 
HIV-1Integrase IN is a 32 kDa protein with 288 amino acids encoded by pol gene as a part of 
Gag-Pol polyprotein which is processed by HIV-1 protease (Delelis et al. 2008). Integrase 
belongs to superfamily of polynucleotidyl transferases which includes other proteins like Mu 
transposase and RNaseH (Dyda et al. 1994). Integrase enzyme catalyzes the integration of the 
reverse transcribed viral DNA into the host genome (Bushman and Craigie 1991, LaFemina, 
et al. 1991, Engelman and Craigie 1992), which is essential step of virus  
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replication. IN has a three domain structure: N-terminal domain (NTD), Catalytic core 
domain (CCD) and C-terminal domain (CTD) (Figure1) (Engelman and Craigie 1992, 
Engelman et al. 1993, van Gent et al. 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiqure1: Domain organisation and amino acid residues conserved among HIV-1 integrase proteins. The enzyme 
comprises the N-terminal domain (NTD), residues 1–49, catalytic core domain (CCD), residues 50–212 and C-
terminal domain (CTD) residues 213– 288. The aspartic acid (D64, D116) and glutamic acid (E152) residues in 
the CCD form the DDE motif (red font), play a major role in integration. Lysine (K) 159 a conserved residue in 
transposase protein, binds to the viral LTR. Tryptophan (W) 235 in the CTD is conserved only among the 
retroviral integrases. (Adapted from (Vandegraaff and Engelman, 2007) 
 
N-terminal domain (residue 1-51) is formed by a bundle of three α-helices and has a HHCC 
motif (Cai, Zheng et al. 1997), which is conserved in retroviral integrases. The HHCC motif 
indicates Histidine and Cysteine residues H12, H16, C40 and C43 which interacts with zinc 
with a stoichiometry of 1:1 and stabilizes the interaction between the helices (Zheng, Jenkins 
et al. 1996). HHCC motif is proposed as zinc finger structure based on the similarity to the 
CCHH motif found in transcription factor TFIIIA. Zinc binding to HHCC motif promotes 
multimerization and enhances the catalytic activity of IN (Zheng, Jenkins et al. 1996). 
Substitution of any one of the conserved histidine or cysteine residues in this motif would be 
expected to disrupt the zinc finger, but mutation of IN at these residues does not completely 
abolish catalytic activity in vitro (Cannon et al. 1994). 
 
Catalytic Core domain (residue 52-211) has DD35E motif (figure 2) which is conserved 
among retroviral integrase, and transposase protein. These acidic residues (D64, D116, E152)  
co-ordinate with Mg
2+
 or Mn
2+
 (Goldgur, Dyda et al. 1998) and catalyse the 3` processing 
and strand transfer activities of viral DNA. Mutants of active site residues (D64, D52, E116) 
show most drastic effect on all in vitro IN activities such as 3` processing, strand transfer and 
disintegration. (Engelman & Craigie, 1992; Kulkosky et al. 1992, van Gent et al. 1993). CCD 
also takes part in multimerization, CCD-CCD interface is fairly large (~1,650 Å2) and 
include Glu85, Ala86, Tyr99, Phe100, Lys103, Trp108, Gln177 and Asn184 residues at the 
interface (Christ et al. 2010). 
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Figure 2. Structure of catalytic core dimer (Pdb Id 1BIS): CCD is formed by five-stranded mixed β sheet 
flanked by helices. The catalytic residues of the D, D (35) E sequence couloured in red and these residues are 
located in opposite face of the CCD dimerization interface. Dimerization of the CCD domain involves 
predominantly hydrophobic interactions. (Mariusz et al 2011) 
 
C-terminal domain (residue 212-288) is least conserved domain. NMR structure of CTD is 
dimeric with each monomer consisting of five β strands (residue 222-229, 232-245, 248-253, 
256-260, 265-268) arranged in an antiparallel manner (figure 3). Topology of CTD structure 
resembles the Src homology3 (SH3) domain (Eijkelenboom et al. 1995) with highly basic 
amino acid residues interacting with DNA in a nonspecific manner (Chen et al. 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Monomeric structure of C-terminal Domain. Three stranded β sheet coloured in blue and two stranded 
 
β sheet coloured in red are shown which are connected by the loops. Length of strand is denoted by the labelled 
residue. (Adapted from (Eijkelenboom, Lutzke et al. 1995) 
 
1.3 TWO–DOMAIN STRUCTURE OF HIV-1 INTEGRASE 
 
 
Two-domain crystal structures comprised of the CCD and CTD (Chen et al 2000) or NTD 
and CCD (Wang et al. 2001) showed dimeric organizations. In two domain structure of 
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NTD-CCD, NTD is linked to the CCD through a linker segment of amino acids 47–55 shown 
in Figure 4 (right) with an arrow (Wang et al. 2001). Another flexible loop comprised of 
residues 187–194 connects the CCD with the CTD is shown in Figure 4 (left) (Chen et al. 
2000). Dimer interfaces for individual NTDs and CTDs with CCD differs for two domain 
system (Kessl et al. 2009). Dimer can catalyse in vitro 3` processing and strand transfer 
reaction but fails in concerted integration because the active sites of integrase are located on 
opposite sides of the dimeric CCD structure separated by 40 A °, while the distance between 
target scissile bonds in ideal B form DNA is close to 18 A ° so tetramer of a integrase (Hare 
et al. 2009) (figure 5) which is a compact structure is necessary to accomplish concerted 
integration of both LTRs (8 –10 bp) into host DNA. IN tetramer is a dimer-of-dimer and 
tetramerisation is primarily mediated by intermolecular interactions between NTD-CCD 
(Wang et al. 2001, Hare et al. 2009). Within tetramer a pair of inner NTDs mediates stable 
dimer-dimer interactions whereas remaining (outer) NTDs do not participate in the 
tetramerisation. The NTD-CCD interface within the monomer includes a well-defined salt 
bridge between Glu11 and Lys186 and hydrophobic interactions involving Tyr15, Trp132, 
Val165, Phe181, and Ile182. And an additional salt bridge is formed between Asp25 and 
Lys188 shown in figure 6 (Hare et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Two–domain structure of HIV-1 integrase. Left figure. HIV-1 CCD-CTD (pdb Id 1EX4) dimer 
formed by two monomers (green+purple and blue+cyan). catalytic core domain for two monomers are shown in 
purple and cyan colour dimer and C-terminal domain are shown in green and blue. Right figure. HIV-1(1-212) 
dimer (pdb Id K6Y) formed by two monomer (green+orange and blue+yellow). NTD are coloured blue and 
green) and CCD are coloured yellow and orange. (Adpted from (Chen, Krucinski et al. 2000, Wang, Ling et al. 
2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiqure 5. Ribbons diagram of the integrase tetramer. The integrase full-length tetramer 
formed by superposition of the catalytic core domain of the HIV-1 IN52-288 structure (PDB 
code 1EX4) onto the catalytic domains of IN1-212. A,B,C and D reprasents the four 
monomers having CCD and NTD are shown. (Adapted from Wang et al. 2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The NTD-CCD interfaces. NTD (yellow) of one dimer interact with CCD (blue) of other 
dimer. CCD (green) also takes part in interaction. Salt bridge formed between D25:E198 and 
E11:K186 other residue shown takes part in hydrophobic interaction. (Hare et al. 2009) 
 
 
 
1.4 FUNCTION OF CATALYTIC CENTRE MOTIF OF 
INTEGRASE PROTEIN (DD35E). 
 
 
DD35E Motif plays central role for integration reaction by coordinating with two 
divalent cations (Mg2+ or Mn2+). One metal ion functions as a general base. It 
increases the partial negative charge of the incoming nucleophile i.e water by 
deprotonation. The second metal ion functions as a general acid that assists the 
leaving of 5` phosphate oxygen anion of GT dinucleotide and stabilizes a 
 
 
pentavalent transition state by coordination of the non-bridging oxygen atoms at the 
cleavage site (Figure 7) (Haren et al. 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Role of divalent metal ions in catalysis. Catalytic pocket containing the penta coordinated 
phosphate in the transition state is shown. One Mg2+ ions proposed to act as a Lewis acid is 
coordinated with two aspartate residues (D64, D116) , the oxyanion of the leaving group and a 
nonbridging oxygen atom. The second Mg2+ is also shown to complex with the nonbridging oxygen 
and to act as a base for deprotonization of the incoming nucleophile i.e water. (Adapted from (Haren 
et al. 1999) 
 
 
 
1.5 MECHANISM OF RETROVIRAL DNA INTEGRATION 
 
Integration is a two steps process  
1) 3` end processing   
2) strand transfer reaction  
 
 
IN binds to the short viral DNA sequence (12-20 bases) called attachment sites 
shown in figure 8 present at end of long terminal repeats (LTR) which initiates the 
3’ processing (Katzman and Katz 1999). 
 
 
 
 
 
 
 
 
 
Fiqure 8. The HIV-1 DNA end. GT dinucleotide which undergoes 3’processing shown in italics at 3` 
end. Amino acids residues Q62, Q143, Y148, K156 and K159 within catalytic core domain cross 
links to viral DNA end and positions the viral DNA for proper 3’ processing. (Adapted from Haren et 
al. 1999) 
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3` processing takes place in the cytoplasm after the cDNA is formed form viral 
RNA. IN uses water molecule as nucleophile to hydrolyze GT dinucleotide from 
each 3’ end of the viral DNA and forms 3’OH which act as nucleophile in strand 
transfer reaction (figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Mechanism of HIV-1 DNA integration. (a) A tetramer of integrase engage two ends of 
HIV-1 DNA. (b) In strand transfer reaction integrase uses the 3’-hydroxyl groups of the cleaved viral 
DNA to cut the target in a staggered fashion (vertical arrows), which joins the viral 3’ ends to the 5’-
phosphates of the cut (c) The recombination intermediate formed by integrase DNA-strand-transfer 
activity comprises joined viral 3’ ends but free 5’ ends. (d) Gap repair of the DNA recombination 
intermediate yields the integrated provirus flanked by a 5 bp duplication of target DNA (Adapted 
from Vandegraaff and Engelman 2007). 
 
Strand transfer reaction takes place in nucleus and after nuclear entry of processed 
viral DNA, IN uses the 3` hydroxyl groups of the cleaved viral DNA to cut the 
target DNA at the transcriptional active sites and joins the viral 3` ends to the 5` 
phosphates of the cut. Integration process is completed by cleavage of unpaired 
dinucleotide from 5` end of viral DNA which is mediated by integrase and repair of 
single stranded gap with help of host repair proteins such as DNA-PK, DNA ligase 
IV, Ku and XRCC4. 
 
Recombinant integrase is capable of catalysing two reactions (3` processing and 
strand transfer reaction) of integration process in absence of other viral and cellular 
proteins. However studies show that in vivo integration process involves cellular 
protein like Importin 7, Lens Epithelium Derived Growth Factor (LEDGF/p75), 
Barrier to Auto integration Factor (BAF), Gemin 2, High Mobility Group 
chromosomal protein A1 (HMGA) and viral protein like matrix, reverse 
transcriptase, and nucleocapsid. These viral and cellular protein form nucleoprotein 
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complex called preintegration complex (PIC), assisting the viral genome into 
cellular genome. The IN can reverse the strand transfer reaction by site selective 
cleaving of the integrated DNA. This reaction is called disintegration which is just 
reverse of strand transfer reaction occurring only in vitro. (Chow et al. 1992). 
 
 
 
1.6 INTEGRASE MUTANTS 
 
Reverse transcription products of HIV-1 RNA are linear and circular DNA. These 
linear DNA are substrate of viral integration and circular DNA are dead end 
products. Replication-defective integrase mutants of HIV-1 can be grouped into one 
of two phenotypic classes (Engelman 1999) 
 
Class I Mutants specifically blocks at integration step as a result they are defective 
in 3’processing and strand transfer reaction. Reverse transcription is not affected 
and number of LTR circle is increased which acts as marker in class I mutants. 
Example: Mutant of catalytic triad (D64, D116, E52) prior to integration (reverse 
transcription) which results in the reduction in the level of viral DNA synthesis in 
infected cells. In addition to defective reverse transcription, HIV-1 particle assembly 
and release from infected cells are also blocked. Example: H12L, H12N mutations. 
 
1.7 LEDGF 
 
LEDGF/p75 is a member of the hepatoma-derived growth factor (HDGF) related 
protein (HRP) family  ((Dietz et al. 2002). HRPs are characterized by a conserved 
N-terminal PWWP domain (Pro-Trp-Trp-Pro)  (Stec et al. 2000,Qiu  et al. 2002). 
Six human HRP family members have been described: HDGF, HRP1, HRP2, HRP3, 
LEDGF/p75, and LEDGF/p52  (Izumoto et al. 1997, Ikegame et al. 1999,  
Cherepanov et al. 2004). LEDGF/p75 and HRP2 possess affinity for HIV-1 IN with 
their conserved IN-binding domain (IBD)  (Cherepanov et al. 2004). LEDGF/p75 
encoded by the PSIP1 gene and 530-aa protein, PSIP1 also encodes a 333-aa splice 
variant LEDGF/p52 by alternate splicing  (Ge Si and Roeder 1998). 
 
LEDGF/p52 and p75 share NH2-terminal amino acids 1 to 325. LEDGF/ p52 has a 
unique intron at COOH-terminal tail (amino acids 326-333). The NH2 terminus of 
both p52 and p75 contains a PWWP domain (amino acids 1-93), three charged 
domains, a nuclear localization signal and two AT-hook sequences (Gly-Arg-Lys-
Arg-Lys-Ala-Glu-Lys-Gln)  (Vanegas et al. 2005,  Maertens et al. 2004) (figure 10). 
Binding of LEDGF/p75 to DNA in vitro is mediated by the NLS and dual copy of 
the AT-hook DNA binding motif, whereas the N-terminal PWWP domain supplies a 
critical chromatin recognition function  (Turlure et al. 2006). Charged regions (CRs) 
1–3 work with the PWWP domain and AT-hooks to affect chromatin binding. 
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Figure 10: Domain Organization of LEDGF/p75 and related proteins (HRP2 and LEDGF/p52): The 
N-terminal PWWP domain is conserved supplies a critical chromatin recognition function. HRP2 and 
LEDGF/p75 both have IBD domain which interact with CCD domain of HIV-1 integrase. HRP2 has 
homology region III (HR3). LEDGF/p75 and LEDGF/p52 both have NLS, AT-hook, and three 
charged region. The binding of LEDGF/p75 to DNA is mediated by the NLS and a nearby dual copy 
of the AT-hook DNA binding motif .Charged regions (CRs) 1–3 work in concert with the PWWP 
domain.(Adapted from  Engelman and Cherepanov 2008). 
 
 
LEDGF/p75 is closely associated with condensed chromatin in the nucleus. 
LEDGF/p75 is involved in transcriptional activation of stress-related or anti-
apoptotic proteins, such as heat shock protein 27, αB-crystallin, heat-shock protein 
90 and antioxidant protein 2  (Singh, and Fatma 2002) and promotes cell growth and 
protects cells against stress-induced cell death. LEDGF/p75 is identified as a 
common nuclear auto antigen in a variety of inflammatory conditions, such as atopic 
dermatitis, asthma and interstitial cystitis. LEDGF/p75 protein functions as a nuclear 
auto antigen generating an autoantibody response in prostate cancer  (Ganapathy and  
Casiano 2003,  Daniels et al. 2005). LEDGF/p75 can be cleaved by caspases-3 and - 
7, which are the main effector caspases in apoptosis, resulting in two cleavage 
fragments of 65 and 58 kDa. These LEDGF/p75 fragments disturbed the pro-
survival role of LEDGF/p75  (Wu et al. 2002). 
 
NMR structure of the LEDGF/p75 IBD revealed a compact α-helical domain 
possessing topological and structural similarities to HEAT repeat domains  
(Cherepanov et al. 2005). HEAT repeat is an α-helical hairpin structure containing 
37–47 amino acid residues, and found in diverse protein families Huntingtin, 
elongation factor 3, regulatory subunit of protein phosphatase 2A, and PI3-kinase 
TOR. LEDGF/p75 IBD is comprised of only two repeats and therefore classified as 
a pseudo-HEAT repeat analogous topology (PHAT) domain. IN dimer forms a cleft 
like structure, IBD burrows into this cleft (Figure 11). I-365, D-366, and P-409 are 
important residues of LEDGF which are interact with Integrase  (Cherepanov et al.  
2005). The side chain of LEDGF residue Ile-365 projects into a hydrophobic pocket 
formed by IN B-chain residues Leu-102, Ala-128, Ala-129, and Trp-132 and A- 
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chain residues Thr-174 and Met-178. LEDGF residues Phe-406 and Val-408 
interacts Trp-131 in the IN B chain. LEDGF Asp-366 makes a bidentate hydrogen 
bond to the main-chain amides of IN residues Glu-170 and His-171 in chain A. The 
backbone amide of LEDGF residue Ile-365 makes a hydrogen bond to the backbone 
carbonyl group of Gln-168 in chain A  (Cherepanov et al. 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: The overall structure of the CCD–IBD complex. IN chains A and B are colored blue and 
green, respectively; the IBD subunits are violet. The side chains of the DDE catalytic triad are 
shown as yellow sticks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Crystal Structure of the LEDGF/p75-IN Interaction: Residues Ile-365 and Asp-366 of loop 
between IBD helices 1 and 2, project into a pocket at the CCD dimer interface. The bidentate 
hydrogen bond contact between Asp-366 and the backbone amides of IN residues Glu-170 and His-
171 is critical for the protein–protein interaction in vitro, during HIV-1 infection. Ile-365 is buried 
into a hydrophobic pocket predominantly formed by IN residues Ala-128, Trp-132, Leu-102, and 
Met-178. (Adapted from  Engelman and Cherepanov 2008). 
 
LEDGF/p75 is an essential HIV-1 IN cellular cofactor for viral replication (Emiliani 
2005). LEDGF acts as a chromatin tethering factor to facilitate the interaction 
between IN and nuclear chromatin  (Maertens et al. 2003). LEDGF/p75 also directs 
viral DNA integration at AT-rich DNA transcriptional units of the cellular genome  
(Ciuffi et al. 2005,  Shun et al. 2007). 
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The versatile functions of LEDGF/p75 in HIV 1 replication include nuclear import 
of IN, tethering of IN to chromatin for directing viral DNA integration into 
transcriptionally active regions and protection from proteosomal degradation  
(Maertens et al. 2003,  Llano et al. 2004). 
 
1.8 HYPOTHESIS 
 
Human transcriptional co-activator LEDGF/p75 is an essential cellular binding 
partner of HIV-1 integrase. Crystal structure of IN-IBD shows that the side chain of 
LEDGF residue Ile-365 projects into a hydrophobic pocket formed by IN B-chain 
residues Leu-102, Ala-128, Ala-129, and Trp-132 and A-chain residues Thr-174 and 
Met- 178(Cherepanov et al. 2005). Recent study with binding energy calculation is 
showed that residue Met178 of IN interacts with the LEDGF/p75 integrase binding 
domain (IBD)  (Xue 2014). Residue M178 located at the dimeric interface of IN and 
participate in π electron orbital interaction between four amino acids (M178, W132, 
 
F181 and F185). Sulfhydryl–aromatic distance between M178–W132 is 4.13 Å 
(shortest distance between S atom and ring center)  (Al-Mawsawi et al. 2008) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure13: The four-tiered aromatic interaction at the IN dimeric interface: Aromatic interaction 
between M178, W132, F181, and F185 at the dimeric interface (PDB 2B4J) (Adapted from  Al- 
Mawsawi et al. 2008). 
 
Substitution of M178 to C showed decreases in both 3` processing and strand 
transfer activities. M178C was replication incompetent and showed undetectable 
levels of 2-LTR circles and integrated proviral DNA in comparison to WT virus  
(Al- Mawsawi et al. 2008). In another study M178A virus was shown to be 
replication incompetent  (Priet et al. 2003). 
 
Two recently discovered LEDGINs BI-1001 and CX14442  (Xue 2014) and six 
Chemical compounds  (Reddy et al 2014) are also found to interact with residue 
M178. Interaction of M178 residue of IN with LEDGF is only shown by 
computational study. In our study we substitute M178 to Isoleucine and check 
mutation effect on interaction with LEDGF with the help of PULL DOWN. 
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1.9 OBJECTIVES 
 
1. To perform site directed mutagenesis of IN Met178 residue to Ile for analyzing 
its interaction with IBD of LEDGF/p75.  
 
 
2. Expression and purification of mutant His-Tag Integrase mutant M178I protein 
in bacterial expression system.  
 
 
3. To determine the interaction of the mutant IN with IBD of LEDGF/p75 using pull 
down assays.  
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 Chapter 2 
 
 
 
MATERIALS AND METHODS 
 
2.1 CONSTRUCTION OF SITE-DIRECTED IN M178I MUTANT. 
 
Site-directed mutagenesis was done by overlapping PCR using a two-step procedure 
as described below: 
 
Plasmid DNA encoding the mutations M178I within full-length integrase was 
prepared using pfu DNA polymerase. In first step of PCR two sets of primers are 
used in two separate amplification reaction to amplify overlapping DNA 
fragenment. 
 
NR1 (5` CTG GGA TCC TTT TTA GAT GGA ATA GAT AAG GCC 3` ) & NR41 
(CTGCTATTTGTACTGCTGTTTTAAG) primers were used in 1
st
 amplification 
reaction and NR2 (5`ACG ACT CGA GCT AAT CCT CAT CCT GTC TAC TTG 
3`) & NR40 (NR40:CTTAAAACAGCAGTACAAATAGCAG) primers were used 
in 2
nd
 amplification reaction. Primers NR40 & NR41 have desired sequence for 
M178I mutation and also carry change to delete the AflII restriction site. Plasmid 
pINKB6HThr was used as template for both amplification reactions. These two sets 
of reactions produced half fragments containing the mutation site as overlap. In 
second step of PCR, two overlapping half PCR fragments were used as template and 
NR1 and NR2 used as forward and reverse primer. Reaction mixture of all three 
PCR reactions contains 10X Pfu buffer,10mM dNTP, Pfu Polymerase (0.5µl), 5µM 
of primers, 1X BSA . Conditions for all three PCR reaction were same and as 
follows: 1 cycle of denaturation at 95ºC for 3min, 25 cycles of denaturation at 95 ºC 
for 15sec, annealing at 50ºC for 15sec ,extension at 68ºC for 60sec and 1 cycle of 
final extension at 68ºC for 5min. 
 
 
 
2.2 DIGESTION. 
 
After overlap PCR, product and pFT1 LEDGF vector were digested with XhoI and 
BamHI in presence of buffer 4. Digestion reaction was incubated at 37ºC for three 
hours. 
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 2.3 LIGATION. 
 
Ligation of Digested product of mutant and pFT1 LEDGF vector backbone were 
carried out in presence of 1X ligase buffer, 10mM ATP and 0.5µl. This reaction 
mixture was incubated at 18ºC for 4hr. 
 
2.4 SCREENING OF TRANSFORMANTS. 
 
The ligated product is transformed into DH5α competent cells as follows: 
 
1 After Adding 20µl of ligated plasmid DNA to the competent cells and gently tap 
the cells incubate on ice for 15 mins. 
 
2 A heat shock was given to cells at 42°c for 90 sec 
 
3 After heat shock cells were kept on ice for 15 mins. 
 
4 Later 15min 1ml LB broth was added to cells and incubated for 1 hr at 37° in 
incubator. 
 
5 Culture was spun for 2 mins. 
 
6 Cells were resuspended in 100 ul media and spread onto LB plate containing Amp. 
 
7 Plate was incubated at 37°c for overnight in incubator. 
 
 
 
2.5 MINI PREP BY ALKALINE LYSIS METHOD. 
 
1 DH5α colony was picked from LB plate containing Ampicillin antibiotic and 
inoculate into 3 ml LB broth containing Ampicillin. 
 
2 Culture was incubate at 37°c for overnight in shaker incubator (250 rpm) 
 
3 Next day cells were harvested from 1.5 ml culture at 14.8 k for 2 mins at room 
temperature. 
 
4 pellet was resuspended in 100µl of ice cold alkaline lysis solution I (25mM 
Glucose, 10mM EDTA, 50Mm Tris-chloride pH =8) 
 
5 200 µl of freshly prepared alkaline lysis solution II (0.2 N NaOH, 1%SDS) was 
added and invert gently for 5 times and kept on ice for 5mins. 
 
6 150 µl of ice cold Alkaline lysis solution III (it is an acidic solution with pH 4.8 
(potassium acetate) was added and invert gently, kept on ice for 5 mins. 
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7 After Centrifugation at 14.8 k for 5 mins at 4°c supernatant was transferred into 
the fresh tube. 
 
8 Equal volumes of phenol and chloroform in 1:1 ratio (i.e 225ul of phenol and 225 
ul of chloroform) was added to the supernatant and after vortexing centrifuged at 
14.8 k for 5 mins at room temperature. 
 
9 Aqueous upper layer was transferred to fresh tube and add 0.1 volumes of 3M 
Sodium acetate (i.e 45ul) and 2 volumes of absolute ethanol mixed it by vortexing. 
 
10 After centrifugation at 14.8 k for 10 mins at 4°c pellet was washed with 70% 
Ethanol. 
 
11 Pellet was kept for drying at 37°c incubator for 15 min 
 
15 Dried pellet was dissolved in 50µl of TE buffer (10mMTris cl PH 8,1mM 
EDTApH8) and added 1µl of RNase. 
 
 
 
2.6 SCREENING OF CLONE 
 
Screening of clone was done by PCR DNA isolated from mini prep method was 
used as template DNA. Reaction mixture contains 1X Pfu buffer,1mM dNTP, Pfu 
Pol, 0.2 µM of each NR1 and NR2 primers and 1X BSA. Reaction condition was 
similar as for overlap PCR. PCR product was checked on 0.6% agrose gel. 
 
 
 
2.7 SCREENING OF MUTANT 
 
pRA12 mutant was screen by AflII digestion. Two reactions were set, one as control 
with pINKB6HThr (wild type) and other with pRA12 (mutant type). Control 
reaction has 2µg pINKB6HThr and mutant has 2µg of DNA isolated from mini prep 
method (pRA12). Reaction product was incubated at 37°c incubator for 5 hr. 
Digestion product was checked on 0.6% agrose gel at 50Volts. 
 
2.8 INSERT RELEASE 
 
For insert release two reactions were set, one for wild type pINKB6H and other for 
mutant pRA12. Digestion of pRAKB6HThr was performed with XhoI and XbaI. 
Digestion of pRA12 was done with XhoI and BamHI. 
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 2.9 EXPRESSION OF PROTEIN 
 
For expression of mutant IN, DNA isolated from Midi prep method was transformed 
in BL21 DE3 pLyS competent cells. Transformed colony was inoculated in 3ml LB 
broth containing 50µg /ml ampicillin (3 µl of 50mg/ml stock) and 30µg/ml 
chloramphenicol (3µl of 30mg/ml) and incubated overnight at 37°c 250 rpm. Next 
day 5% preinoculam was used for expression of mutant protein in 200ml LB broth 
containing 50µg/ml ampicillin. And induction was done by IPTG (1 mM) at 
absorbance of 0.6–0.7 optical density at 600 nm. After induction, culture was 
allowed to grow for an additional 4 h at 28 °C. This was followed by centrifugation 
of the cells, at 5000 rpm at 24°C for 15min. Cell pellet was resuspended in 5ml lysis 
buffer (50mM TrisCl p7.4, 15mM imidazole, 1MNaCl, 7.5mM CHAPS, 0.5mM 
PMSF). The resuspended pellet was incubated for 30 min at room temperature after 
adding 0.3mg/ml lysozyme. The cells were lysed with sonication. Lysate was 
centrifuged at 14.8k, 4°C for 15min. The supernatant was loaded onto a 1 ml Ni2+-
nitrilotriacetic acid agarose column pre-equilibrated with buffer containing 15mM 
imidazole, 1M NaCl and 50mM TrisCl. After 1hour nutation of beads with 
supernatant, beads were loaded onto column, column was washed with 30 column 
volumes of wash buffer containing 50mM imidazole, 1M NaCl and 50mM TrisCl. 
Integrase was eluted with elution buffer containing 400mM imidazole, 1MNaCl, 
7.5mM CHAPS and 0.5mM PMSF. Elution fraction having mutant IN were dialyzed 
against buffer 500 mM NaCl, 50 mM Tris-Cl pH 7.5. Dialyzed mutant protein was 
stored in storage buffer having 0.5mM PMSF, 1X cocktail inhibitor, 5mM DTT, 
7.5mM CHAPS, 50%glycerol at -20°C. Protein concentration was determined by the 
Bradford method with purified BSA as a standard. 
 
 
 
 
 
 
PULL DOWN 
 
Binding of IN to IBD was assayed in pull-down buffer (PB): 150 mM NaCl, 25 mM 
Imidazole, 2mM MgCl2, 0.1% NP40, 50 mM Tris HCl pH 7.4. A 4 μg of 
recombinant His6-tagged HIV-1 IN were incubated with 3 μg of IBD in 200 μl of 
PB and followed by 30min nutation at 18°C. Samples were supplemented with 50 μl 
 
(settled beads volume) of Ni-charged resin.The mixtures were kept for nutation at 
18°C. Beads were recovered by centrifugation and washed with 1 ml of ice-cold PB. 
Beads were boiled in 12µl 1XTris-glycineand 5µl dye. Eluted proteins were 
separated by SDS-PAGE. 
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 Chapter 3 
 
 
 
RESULT AND DISCUSSION 
 
3.1 SITE DIRECTED MUTAGENESIS OF HIV-1 IN MET178 RESIDUE TO 
ILE: 
 
IN1-288/M178I mutant was generated by overlap PCR. In first step of overlap PCR 
two fragments were generated using two sets of primers forward/antisense and 
sense/reverse primers of which sense and antisense will carry nucleotide change for 
M178I. In the second step of overlap PCR two fragments obtained in first step of 
overlap PCR were used as templates with NR1—NR2 primer sets to generate full 
length IN M178I. PCR products were checked on agarose gel, shown in figure 14. 
DNA fragment produced with NR1/NR41 primers showed band near 500bp and 
fragment produced with NR2/NR40 primers showed band near 300bp shown in 
Figure 14A. Overlap PCR product with NR1-NR2 showed band between 800 and 
900bp as shown in Fig 14 B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Overlap PCR for generating IN M178I mutation: A) First step of overlap PCR using 
NR1-NR41 and NR2-NR42 generating two fragments around 500bp and 300bp. B) Second step of 
overlap PCR using NR1-NR2 generating full length Mutant IN M178I of expected size 864bp. 
 
 
 
3.2 SCREENING OF CLONE AND MUTATION. 
 
Eight colonies were obtained after transformation of ligated product of pFT1 
LEDGF and mutant IN M178I. The colonies were picked into 3ml of LB with 
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ampicillin overnight. Mini prep plasmid DNA isolation was done with 1.5ml culture. 
After isolation, plasmid DNA was checked on agarose gel as shown in Fig 15. 
Colony 4 and 6 DNA showed lower mobility as compared to pFT1 LEDGF/p75. 
These were screened further by PCR amplification using NR1-NR2 primer set. PCR 
product was checked on agrose gel which showed that clone 4 and clone 6 formed 
expected band of 864bp length as shown in Fig 16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Mini prep plasmid DNA isolation. DNA isolated from eight colonies were checked on gel. 
pFT1 LEDGF was used as Control. Clone 1, 2 3, 7, and 8 were showing same mobility as that of 
pFT1 LEDGF. Clone 4 and Clone 6 showed lower mobility as compared with pFT1 LEDGF. 
 
 
 
Insert release was checked by digestion of pRA12 with XhoI and BamHI and for 
digestion of pINKB6HThr was with XhoI and XbaI enzymes. For pRA12 digestion 
with XhoI and BamHI an insert release of 864 bp and for pINKB6HThr digestion 
with XhoI and XbaI an insert release of 915bp was obtained (fig 17). 
 
For screening M178I mutant in IN, AflII digestion was performed, pRA12 (plasmid 
from colony 4) loses AflII site after generating M178I mutation and wild type IN 
(pINKB6HThr) retains AflII site. After digestion with AflII, a linear fragment was 
obtained for pINKB6HThr while pRA12 showed undigested nicked and supercoiled 
DNA, as can be seen in Fig 18 confirming the presence of M178I mutation in colony 
4 DNA of pRA12. 
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Figure 16 Screening of Clone using PCR: NR1-NR2 PCR amplification product of clones 4 and 6 
mini DNA was shown. Both the clones showed the expected amplification product of 864 bp. The 
100bp ladder used as marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Insert release of pRA12. Insert release was analyzed on agrose gel with 1Kb ladder as 
marker. pINKB6HThr uncut is used as control . pINKB6HThr digested with XhoI and XbaI showed 
insert release of 915 bp and pRA12 digested with XhoI and BamHI showed the insert release of size 
864 bp, as expected. 
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Figure 18 AflII digestion of pRA12. Digestion of pRA12 was analysed on agrose gel with 1 Kb 
marker. pINKB6HThr with AflII site digested with AflII restriction enzyme gave linearized vector 
where as pINKB6HThr uncut showed two forms supercoiled and nicked one on the gel. pRA12 cut 
with AflII restriction enzyme shown same band pattern as uncut pRA12, which indicates the loss of 
AflII site as a result of generating M178I mutation in IN. 
 
3.3 PROTEIN PURIFICATION OF IN M178I: 
 
IN1-288/M178I mutant protein was purified from the soluble fraction after lysis of 
cells. His Tag at N-terminus of the IN M178I protein permitted rapid purification by 
nickel-affinity chromatography as described in materials and methods, homogenous 
preparation of M178I mutant of IN was obtained. Purification was analyzed by 
SDS-PAGE (fig 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 Protein purifation of pRA12. Protein is eluted with 400mM imidazole and fractions were 
analyzed by SDS-PAGE. Pellet, Lysate, flow through, wash and 5 elution fractions are loaded on gel. 
Protein ladder was used as Marker. Protein was dialyzed from elution fraction 4 and 5 and used for 
assays. 
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3.4 Pull Down 
 
Pull down of IBD using His6-tag IN was done for analysis of interaction. Wild type 
IN with wild type IBD and wild type IN with mutant IBD D366N were used as 
positive and negative controls. Wild IN shows interaction with wild type IBD but 
did not show interaction with D366N mutant of IBD, as was demonstrate earlier in 
literature (Cherepanov et al 2005). Mutant IN M178I shows negligible interaction 
with wild type IBD as can be seen in figure 20. Quantification of pull down assay 
indicates a 93% reduction in interaction between IBD of LEDGF/p75 and M178I 
mutant of IN as shown in graph 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 His6-tag pull-down assay for the N-terminally His6-tagged IN mutants. The IN mutant 
proteins were incubated with IBD and Ni2+-NTA agarose beads. The pulled-down proteins were 
checked on separated on a SDS–PAGE gel and. Wild type IN with wild type IBD and wild type IN 
with mutant IBD D366N were used as control. Wild IN shows interaction with type IBD but did not 
show interaction with mutant IBD D366N. Mutant IN M178I shows reduced interaction with wild 
type IBD. 
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Graph 1 Quantification of pull down of IBD with mutant His6 tag IN M178I. Wild type IN 
interaction with wild type IBD is set to 100% and with mutant IBD D366N serves as negative  
control. Mutant IN M178I shows a 93% loss of interaction with wild type IBD of LEDGF/p75. 
 
 
3.5 DISCUSSION 
 
LEDGF/p75 is an important cellular binding partner of HIV-1 integrase. Residue Ile 
365 of LEDGF projects into a hydrophobic pocket formed by IN B-chain residues 
Leu-102, Ala-128, Ala-129, and Trp-132 and A-chain residues Thr-174 and Met-
178. With the help of pull down assay, this study shows that M178 plays an 
important role in interaction between LEDGF/p75 and IN. Pull down assay shows 
that mutation of IN at M178 results in a nearly 90% loss of interaction with IBD. 
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 Chapter 4 
 
 
 
CONCLUSION 
 
 
LEDGF/p75 is important cellular co factor for HIV-1 replication. LEDGF/p75 
interacts with HIV-1 IN. In this study, HIV-1 IN has been mutated at residue M178 
using overlap PCR and interaction of purified mutant with IBD of LEDGF/p75 was 
analyzed. A 90% decrease in interaction between M178I mutant of IN and wild type 
IBD of LEDGF/p75 indicates that M178 is makes crucial interactions with I365 of 
IBD of LEDGF/p75. 
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